Skip to content

Study · Randomized controlled trial · n = 28 · 2005

3 results

Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

Hurley M, Yao W, Lane NE

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA19 Aug 2005Cited by 17 (Europe PMC)

PMID16133640 (opens in a new tab)DOI10.1007/s00198-005-1998-x (opens in a new tab)PepBankPUB-16133640
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In women with glucocorticoid-induced osteoporosis, hPTH increased osteocalcin more than 150% above baseline at 3 months, sustained throughout treatment.

    In plain wordsIn women with glucocorticoid-induced osteoporosis, hPTH increased a bone formation marker above baseline throughout treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteocalcin
    Study

    n = 28

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 U/day · injection · 12 monthsAs given in this study (human).

    Measurements

    Osteocalcin change from baseline
    > 150%
    hPTH group at 3 months, maintained throughout treatment

    Source sentences

    Summary
    In the hPTH group, OST increased by more than 150% above baseline at 3 months and was maintained at this level throughout the treatment period.
    1 context sentence
    Summary · context
    All studied subjects (n=51) had postmenopausal osteoporosis, had been receiving long-term treatment with glucocorticoid plus estrogen or estrogen/progesterone and were randomly allocated either to a group receiving hPTH, 400 U/day (n=28), or to a control group (n=23).
  2. 02HumanRandomized controlled trialMechanism

    In women with glucocorticoid-induced osteoporosis, hPTH increased BSAP over 80% at 3 months and maintained it 90% above baseline thereafter.

    In plain wordsIn women with glucocorticoid-induced osteoporosis, hPTH increased bone-specific alkaline phosphatase above baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone-specific alkaline phosphatase
    Study

    n = 28

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 U/day · injection · 12 monthsAs given in this study (human).

    Measurements

    BSAP change from baseline
    > 80%
    hPTH group at 3 months
    BSAP change from baseline
    90%
    hPTH group, maintained for the next 9 months

    Source sentences

    Summary
    BSAP had increased more than 80% over the baseline level at 3 months and was maintained at 90% above baseline for the next 9 months.
    1 context sentence
    Summary · context
    All studied subjects (n=51) had postmenopausal osteoporosis, had been receiving long-term treatment with glucocorticoid plus estrogen or estrogen/progesterone and were randomly allocated either to a group receiving hPTH, 400 U/day (n=28), or to a control group (n=23).
  3. 03HumanRandomized controlled trialMechanism

    In women with glucocorticoid-induced osteoporosis, hPTH increased bFGF by 45% at 3 months and more than 90% by 12 months.

    In plain wordsIn women with glucocorticoid-induced osteoporosis, hPTH increased basic fibroblast growth factor above baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBasic fibroblast growth factor
    Study

    n = 28

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 U/day · injection · 12 monthsAs given in this study (human).

    Measurements

    bFGF change from baseline
    45%
    hPTH group at 3 months
    bFGF change from baseline
    60%
    hPTH group at 6 to 9 months
    bFGF change from baseline
    > 90%
    hPTH group at 12 months

    Source sentences

    Summary
    bFGF levels had increased by 45% at 3 months, 60% at 6 to 9 months (P<0.05) and had increased more than 90% from baseline by 12 months (P<0.05).
    1 context sentence
    Summary · context
    All studied subjects (n=51) had postmenopausal osteoporosis, had been receiving long-term treatment with glucocorticoid plus estrogen or estrogen/progesterone and were randomly allocated either to a group receiving hPTH, 400 U/day (n=28), or to a control group (n=23).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.